Dublin, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/97b65k/epigenetics)
has announced the addition of the "Epigenetics
Technology Market (Epigenomics, DNA Methylation, Histone
Modifications, RNA Interference, Cancer Therapeutics, Personalized
Medicine) (2012 - 2017)" report to their offering.
Over the last decade, genomics and proteomics have been used as key
tools to discover potential drug targets and to better understand
the complexities of biology. To balance research in these areas,
epigenetics offers a potential opportunity in understanding the
basis of various diseases in a different approach. Thus,
epigenetics is study of heritable changes in genome function and
gene expression had opened the new gate of biology to understand
the basis of diseases and presents incredible opportunities for
disease diagnosis and drug discovery.
Report covers the market by therapeutics sector in oncology
conditions, non-oncology indications and personalized medicine. The
report also covers the market by research and diagnostics sector in
gene regulation studies, biomarker detection and drug discovery. In
addition, it also includes the factors driving and restraining the
market and covers the market scenario in the U.S., Europe, Asia and
the Rest of the World (ROW). This report will provide the company
profiles of key companies along with the competitive
analysis.
The Global Epigenetics
market is showing a double digit growth (CAGR 25%) due to
supportive factors such as, (i) huge amount of funds and
investments, (ii) increasing partnerships and collaborations, and
(iii) rapid screening tools. Epigenetics is used in the
identification of new epigenetic biomarkers, which will aid in
better diagnosis and prognosis of diseases. While there are factors
favoring the market growth, there are concerns such as change in
re-imbursement systems and lack of predictive markers holding back
the growth of this market. However, the positive aspects in this
field may very well offset the market restraints to aid the market
grow at an exceptional rate.
Key Topics Covered:
1. INTRODUCTION
2. EXECUTIVE SUMMARY
3. EPIGENETICS - TECHNOLOGY LANDSCAPE ANALYSIS
4. EPIGENETICS - MARKET LANDSCAPE ANALYSIS
5. TECHNOLOGY INVESTMENT POTENTIAL
5.2 INVESTMENT OPPORTUNITIES
6. EPIGENETICS - TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY
GEOGRAPHY
7. EPIGENETICS COMPETITIVE LANDSCAPE
8. INTELLECTUAL PROPERTY AND RESEARCH STRENGTH ANALYSIS
9. ANALYST INSIGHTS AND RECOMMENDATIONS
10. COMPANY PROFILES
11. APPENDIX
12. GLOSSARY
Companies Mentioned
- 4SC (GERMANY)
- CELGENE (U.S.)
- CELLCENTRIC (U.K.)
- CH3 BIOSYSTEMS (U.S.)
- COVARIS INC. (U.S.)
- EISAI CO. LTD. (JAPAN)
- EPIONTIS (GERMANY)
- EPITHERAPEUTICS (DENMARK)
- EPIZYME (U.S.)
- KARUS THERAPEUTICS (U.K.)
- MERCK MILLIPORE (U.S.)
- RIBOMED BIOTECHNOLOGIES (U.S.)
For more information visit http://www.researchandmarkets.com/research/97b65k/epigenetics
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals